After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
CTLT belongs to the Healthcare sector of the NYSE while operating in the Drug Manufacturers – Specialty & Generic industry. The current market capitalization of Catalent Inc. is $10.18B. A total of 1.96 million shares were traded on the day, compared to an average of 2.74M shares.
In the most recent transaction, Gunther Scott sold 387 shares of CTLT for 56.20 per share on Mar 15 ’24. After the transaction, the SVP, Quality & Reg. Affairs now owns 29,506 company shares. In a previous transaction on Aug 31 ’23, Ryan Michelle R bought 1,000 shares at 49.98 per share. CTLT shares that Director owns now total 1,979.
Among the insiders who bought shares, GREISCH JOHN J acquired of 21,000 shares on Aug 30 ’23 at a per-share price of $50.24. This resulted in the Executive Chair holding 34,000 shares of CTLT after the transaction. In another insider transaction, Maselli Alessandro sold 2,071 shares at $44.54 per share on Aug 24 ’23. Company shares held by the President & CEO now total 88,004.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, CTLT has a high of $66.41 and a low of $31.45.
As of this writing, CTLT has an earnings estimate of $Confluent, Inc. per share for the current quarter. EPS was calculated based on a consensus of iShares 20+ Year Treasury Bond estimates, with a high estimate of $Calliditas Therapeutics AB per share and a lower estimate of $Catalent, Inc..
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. CTLT’s latest balance sheet shows that the firm has $538.00M in Cash & Short Term Investments as of fiscal 2022. There were $4.22B in debt and $1.10B in liabilities at the time. Its Book Value Per Share was $20.41, while its Total Shareholder’s Equity was $4.78B.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CTLT is Buy with a score of 3.40.
